News
Homepage
/
News
/
In 2016

News Classification

Check category

News Center

Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA 2024-12-04 15:57:06
Recently, Viwit Pharmaceuticals received the "Drug registration certificate" issued by China National Medical Products Administration (NMPA) for Brimonidine Tartrate and Timolol Maleate Eye Drops. The approval number is H20249650. This signifies that the product has received official approval for the Chinese market and has successfully passed the generic drug consistency evaluation.
Viwit's Nitroglycerin Sublingual Tablets Approved by FDA 2024-10-22 14:48:28
Recently, Viwit Pharmaceuticals' proprietary developed Nitroglycerin Sublingual Tablets (strengths: 0.3 mg, 0.4 mg, 0.6 mg) received a marketing authorization letter from the US Food and Drug Administration (US FDA), ANDA number: 218583, signifying the product's official approval in the US market.
Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated" 2024-09-23 14:46:43
From July 15 to 19, 2024, FDA inspectors conducted a five-day on-site cGMP (Current Good Manufacturing Practice) inspection of Viwit Pharmaceuticals Co., Ltd. (referred to as Viwit API manufacturing facility). Recently, the FDA's official website showed that Viwit's API manufacturing facility successfully passed the cGMP on-site audit with a perfect result of NAI, meaning "Zero 483". This is the second time Viwit's API manufacturing facility has successfully passed the U.S. FDA audit, further affirming Viwit’s robust and continuous production management and quality systems.
Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US. 2024-09-18 09:00:00
Viwit Pharmaceuticals (Viwit), an innovation driven biopharmaceutical and healthcare company has entered into an exclusive licensing and supply agreement with Zydus Lifesciences Ltd.’s wholly owned subsidiary, Zydus Lifesciences Global FZE for Gadobutrol Injection (generic version of GADAVIST) and Gadoterate Meglumine Injection (generic version of DOTAREM) for the US market.
Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US! 2024-08-14 11:55:51
Recently, Viwit Pharmaceutical’s self-developed Lifitegrast API has completed the registrations in China and the United States. The API registration number is Y20240000726, and the US DMF number is 040172.
Viwit Pharmaceutical's Varenicline Tartrate Tablet receives official approval from South Africa 2024-07-15 10:01:41
Recently, theViwit independently developed smoking cessation drug Varenicline (Tartrate) Tablets, in strengths of 0.5 mg and 1 mg, received the Drug Registration Certificate issued by the South African Health Products Regulatory Authority (SAHPRA).

In 2016

01-24

Viwit 2016 Annual Gala Successfully Held

On January 24th, all employees of Viwit held the 2016 Spring Festival in the blue brick and red tile Longyuan Ancient Town. The company's president Wei Yanjun gave a congratulatory message to all employees, affirmed the work in 2015, thanked all the wise people for their hard work over the past year, expressed their expectations for future development, and sent the deepest to all employees and their families. blessing.
Viwit 2016 Annual Gala Successfully Held
04-27

Mr. Wei attended and exchanged keynote speeches on talent cooperation and entrepreneurship in Shandong (East US)

On the evening of April 26, New York time, Dr. Wei Yanjun, Chairman and President of Viwit, delivered a keynote speech at the Shandong (East US) Talents Cooperation and Entrepreneurship Exchange.
Mr. Wei attended and exchanged keynote speeches on talent cooperation and entrepreneurship in Shandong (East US)
06-10

Welcome participants in CPhI China 2016, booth number W2A09

The 16th CPhI China 2016 will be held at Shanghai New International Expo Center from June 21-23, 2016. Welcome to patronize Viwit, booth number: W2A09. If you would like to make an appointment in advance, please email us at service@viwit.com.
Welcome participants in CPhI China 2016, booth number W2A09
10-24

Congratulations to Viwit Pharmaceutical Co.,Ltd

In October 2016, Viwit accepted the 5-day GMP on-site review of the Atazanavir Sulfate API by the Ministry of Health of Mexico (COFEPRIS), and again with "zero defect" results Successfully passed the audit. Following the first COFEPRIS audit in 2014, Viwit successfully passed the on-site inspection with excellent results. Due to the increasing global GMP requirements, this audit is more stringent than in the past, but Viwit has always adhered to the concept of cGMP norms and continued to improve its quality management. The production environment and quality system have left a good impression on the COPRIPRIS auditors. The GMP review by COFEPRIS in Mexico strengthened Viwit's belief in healthy products. Viwit will continue to adhere to the GMP standard, strictly control each link, and provide more safe and high quality API products.
Congratulations to Viwit Pharmaceutical Co.,Ltd
10-24

Congratulations to the successful conclusion of the 2016 CPhI Worldwide exhibition

Congratulations on the successful conclusion of the 2016 World Pharmaceutical Raw Materials Europe Exhibition, and thank all the new and old customers who came to the site for their trust and support. Through this exhibition, we have deepened cooperation with customers and laid the foundation for further expanding the market. We will continue to work hard to create value for our customers.
Congratulations to the successful conclusion of the 2016 CPhI Worldwide exhibition
10-24

Congratulations to Viwit Pharmaceutical Co.,Ltd for passing Cofepris certification of the Ministry of Health of Mexico

In October 2015, Viwit Pharmaceutic Co., Ltd. ushered in the GMP audit of the Atazanavir Sulfate API by the Mexican official Cofepris. After five days of intensive and orderly inspection and certification, we have all zero defects It successfully passed the on-site inspection and finally obtained the GMP certificate issued by the Mexican Ministry of Health Cofepris. The Cofepris certification of the Mexican Ministry of Health further strengthened the company's GMP concept and improved the production management system. At the same time, it opened the door to the Latin American market for the company's sales of APIs and became the cornerstone of future regulatory market certification.
Congratulations to Viwit Pharmaceutical Co.,Ltd for passing Cofepris certification of the Ministry of Health of Mexico
Previous page
1
search
Confirm
Close
About Us
Company Introduction Corporate History Business Introduction Corporate Governance Company Culture Corporate Honors Viwit Family Media Center Video
R&D and Innovation
R&D Innovation Product Pipeline Achievements
Products
Drug Products Biologics APIs Intermediates Boranes OLED Materials
Innovation
CDMO Project Collaboration In-/Out-Licensing Joint Venture
Sustainable
EHS Energy Quality Supplier
News Center
In 2024 In 2023 In 2022 In 2021 In 2020
Join Us
Talent Philosophy Talent Development Salary and Benefits Campus Recruiting Social Recruitment
Contact Us
Online Message Contact Us
dp EN
dp 中文

wz

wz